Sudeep Dhillon, MD
Endocrinology, Diabetes & Metabolism · Pennington, NJNPI 1780904094
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $28,500 of the $44,654 with a category attached, or 63.8%. AstraZeneca accounts for 72.4% of it on its own, with 58 other manufacturers making up the rest. Reporting peaked in 2019 at $21,223 and has fallen 90.5% since, to $2,024 in 2025. Among endocrinology, diabetes & metabolism clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,117 payments — averaging $39.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$32K
- Novo Nordisk$3K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$1K
- Amneal Pharmaceuticals LLC$833
- Mannkind Corporation$454
- plus $6K from 53 others
What the payments were for
- Speaking & faculty fees$28,50064%
- Travel & lodging$1,1783%
- Food & beverage$14,89433%
- Education$820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$31,016
How this compares
$44,654 in reported general payments places this provider in the 90th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 543 | $963,736 |
| MounjaroTirzepatide | 230 | $392,664 |
| JardianceEmpagliflozin | 148 | $177,410 |
| Tresiba Flextouch U-200Insulin Degludec | 203 | $170,744 |
| FarxigaDapagliflozin Propanediol | 184 | $167,849 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 125 | $137,953 |
| RybelsusSemaglutide | 62 | $137,454 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 129 | $135,950 |
| Xigduo XrDapaglifloz Propaned/Metformin | 129 | $121,097 |
| JanuviaSitagliptin Phosphate | 79 | $104,011 |
| Humalog Kwikpen U-200Insulin Lispro | 110 | $101,325 |
| JanumetSitagliptin Phos/Metformin Hcl | 89 | $95,532 |
| TradjentaLinagliptin | 80 | $73,875 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 90 | $60,128 |
| TrulicityDulaglutide | 36 | $46,513 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $2,722 | $1,108,121616 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Jentadueto Xr, Glyxambi | $1,078 | $501,322453 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev | $1,429 | $460,686317 claims |
| MerckJanumet Xr, Januvia, Janumet | $281 | $335,493297 claims |
| AstraZenecaFarxiga | $32,309 | $167,849184 claims |
| AmgenProlia | $435 | $18,03811 claims |
| Antares Pharma, Inc.Xyosted | $303 | $16,29612 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $833 | $6,678543 claims |
| IBSA Pharma Inc.Tirosint | $17 | $6,53020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Pennington
- Taher ModarressiPennington$402K
- Yan WuPennington$13K
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Navtika DesaiHillsborough$408K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.